Key Findings:  These results suggest that the CB2 receptor may represent a new target for modulating the inflammatory reaction induced by mycobacteria.
Type of Study:  Animal Study
Study Result:  Positive
Study Location(s):  Brazil
Year of Pub:  2016
Cannabinoids Studied: 
Terpenes Studied:  ß-Caryophyllene
Receptors Studied:  CB2
Dosage: BCP (0.5-50 mg/kg) or intraperitonealy with GP1a (10 mg/kg) 1 h before the induction of pleurisy or pulmonary inflammation by BCG.
Route of Administration:  Injection, Oral (Ingestion)